跳至主要内容
临床试验/ISRCTN86185157
ISRCTN86185157已完成3 期

A multicentre randomised trial of single dose Radiotherapy compared to Ibandronate for localised metastatic Bone pain

Cancer Research UK (CRUK) (UK)0 个研究点目标入组 580 人开始时间: 2003年6月2日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
580

研究概览

简要总结

2015 Results article in http://www.ncbi.nlm.nih.gov/pubmed/26242893 results

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Histologically or cytologically proven underlying primary malignancy of breast, lung or prostate, or sclerotic bone metastases in a patient presenting with a serum Prostate Specific Antigen (PSA) more than 100ng/ml
  • 2. Bone metastases confirmed radiologically on plain x-ray, isotope scan, Computed Tomography (CT) or Magnetic Resonance (MR) scan
  • 3. Single localised metastatic bone pain receiving optimal analgesics and adjuvant drugs including Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) unless contraindicated.
  • 4. Clinical diagnosis of metastatic bone pain for which radiotherapy is indicated
  • 5. Aged over 18 yrs with no upper age limit
  • 6. Able to comply with pain chart and quality of life assessments
  • 7. Able to give written informed consent.

排除标准

  • 1. Predicted life expectancy less than three months
  • 2. Bisphosphonate treatment within the last six months
  • 3. Any previous treatment that contraindicated radiotherapy or ibandronate or that would interfere with the action of either
  • 4. Unfit to receive radiotherapy and ibandronate
  • 5. Aspirin sensitive asthma in past medical history
  • 6. Pregnancy and lactation

研究者

发起方
Cancer Research UK (CRUK) (UK)

相似试验